Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2019, Article ID 5985923, 8 pages
https://doi.org/10.1155/2019/5985923
Research Article

Identification of Two DNMT3A Mutations Compromising Protein Stability and Methylation Capacity in Acute Myeloid Leukemia

1Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Institute of Hematology “L. e A. Seràgnoli”, Bologna, Italy
2Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola (FC), Italy
3Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy

Correspondence should be addressed to Giorgia Simonetti; ti.rme.tsri@ittenomis.aigroig

Received 26 April 2019; Accepted 11 September 2019; Published 30 October 2019

Academic Editor: San-Lin You

Copyright © 2019 Samantha Bruno et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. Cancer and G. Atlas, “Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia the cancer genome atlas research network,” New England Journal of Medicine, vol. 368, no. 22, pp. 2059–2074, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. M. A. McDevitt, “Clinical applications of epigenetic markers and epigenetic profiling in myeloid malignancies,” Seminars in Oncology, vol. 39, no. 1, pp. 109–122, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. S. F. Chaudry and T. J. T. Chevassut, “Epigenetic guardian: a review of the DNA methyltransferase DNMT3A in acute myeloid leukaemia and clonal haematopoiesis,” BioMed Research International, vol. 2017, Article ID 5473197, 13 pages, 2017. View at Publisher · View at Google Scholar · View at Scopus
  4. S. J. Chen, Y. Shen, and Z. Chen, “A panoramic view of acute myeloid leukemia,” Nature Genetics, vol. 45, no. 6, pp. 586-587, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. R. Rampal, A. Alkalin, J. Madzo et al., “DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia,” Cell Reports, vol. 9, no. 5, pp. 1841–1855, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. E. Pronier, R. L. Bowman, J. Ahn et al., “Genetic and epigenetic evolution as a contributor to WT1-mutant leukemogenesis,” Blood, vol. 132, no. 12, pp. 1265–1278, 2018. View at Publisher · View at Google Scholar · View at Scopus
  7. T. J. Ley, L. Ding, M. J. Walter et al., “DNMT3A mutations in acute myeloid leukemia,” New England Journal of Medicine, vol. 363, no. 25, pp. 2424–2433, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. L. I. Shlush, S. Zandi, A. Mitchell et al., “Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia,” Nature, vol. 506, no. 7488, pp. 328–333, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. H. P. Koeffler and G. Leong, “Preleukemia: one name, many meanings,” Leukemia, vol. 31, no. 3, pp. 534–542, 2017. View at Publisher · View at Google Scholar · View at Scopus
  10. G. Genovese, A. K. Kähler, R. E. Handsaker et al., “Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence,” New England Journal of Medicine, vol. 371, no. 26, pp. 2487–2477, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Jaiswal, P. Fontanillas, J. Flannick et al., “Age-related clonal hematopoiesis associated with adverse outcomes,” New England Journal of Medicine, vol. 371, no. 26, pp. 2488–2498, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. C. B. Cole, D. A. Russler-Germain, S. Ketkar et al., “Haploinsufficiency for DNA methyltransferase 3A predisposes hematopoietic cells to myeloid malignancies,” Journal of Clinical Investigation, vol. 127, no. 10, pp. 3657–3674, 2017. View at Publisher · View at Google Scholar · View at Scopus
  13. X. J. Yan, J. Xu, Z. H. Gu et al., “Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia,” Nature Genetics, vol. 43, no. 4, pp. 309–315, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. G. Marcucci, K. H. Metzeler, S. Schwind et al., “Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia,” Journal of Clinical Oncology, vol. 30, no. 7, pp. 742–750, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. A. F. T. Ribeiro, M. Pratcorona, C. Erpelinck-Verschueren et al., “Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia,” Blood, vol. 119, no. 24, pp. 5824–5831, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Renneville, N. Boissel, O. Nibourel et al., “Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the acute leukemia french association,” Leukemia, vol. 26, no. 6, pp. 1247–1254, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. F. Thol, F. Damm, A. Lüdeking et al., “Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia,” Journal of Clinical Oncology, vol. 29, no. 21, pp. 2889–2896, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. H. A. Hou, Y. Y. Kuo, C. Y. Liu et al., “DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications,” Blood, vol. 119, no. 2, pp. 559–568, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. K. Morita, H. M. Kantarjian, F. Wang et al., “Clearance of somatic mutations at remission and the risk of relapse in acute myeloid leukemia,” Journal of Clinical Oncology, vol. 36, no. 18, pp. 1788–1797, 2018. View at Publisher · View at Google Scholar · View at Scopus
  20. B. Bhatnagar, A. K. Eisfeld, D. Nicolet et al., “Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia,” British Journal of Haematology, vol. 175, no. 2, pp. 226–236, 2016. View at Publisher · View at Google Scholar · View at Scopus
  21. C. Gebhard, D. Glatz, L. Schwarzfischer et al., “Profiling of aberrant DNA methylation in acute myeloid leukemia reveals subclasses of CG-rich regions with epigenetic or genetic association,” Leukemia, vol. 33, no. 1, pp. 26–36, 2019. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Wang, S. Zhang, S.-S. Chuang et al., “Angioimmunoblastic T cell lymphoma: novel molecular insights by mutation profiling,” Oncotarget, vol. 8, no. 11, 2017. View at Publisher · View at Google Scholar · View at Scopus
  23. I. Fried, C. Bodner, M. M. Pichler et al., “Frequency, onset and clinical impact of somatic DNMT3A mutations in therapy-related and secondary acute myeloid leukemia,” Haematologica, vol. 97, no. 2, pp. 246–250, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. H. DöhnerDöhner, E. Estey, D. Grimwade et al., “Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel,” Blood, vol. 129, no. 4, pp. 424–447, 2017. View at Publisher · View at Google Scholar · View at Scopus
  25. E. Papaemmanuil, M. Gerstung, L. Bullinger et al., “Genomic classification and prognosis in acute myeloid leukemia,” New England Journal of Medicine, vol. 374, no. 23, pp. 2209–2221, 2016. View at Publisher · View at Google Scholar · View at Scopus
  26. J. P. J. Issa, G. Roboz, D. Rizzieri et al., “Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study,” Lancet Oncology, vol. 16, no. 9, pp. 1099–1110, 2015. View at Publisher · View at Google Scholar · View at Scopus
  27. W. Chung, A. D. Kelly, P. Kropf et al., “Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia,” Clinical Epigenetics, vol. 11, no. 1, 2019. View at Publisher · View at Google Scholar
  28. R. Itzykson, O. Kosmider, T. Cluzeau et al., “Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias,” Leukemia, vol. 25, no. 7, pp. 1147–1152, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. R. Bejar, A. Lord, K. Stevenson et al., “TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients,” Blood, vol. 124, no. 17, pp. 2705–2712, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. D. Russo, M. Malagola, A. De Vivo et al., “Multicentre phase III trial on fludarabine, cytarabine (ara-C), and idarubicin versus idarubicin, ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients,” British Journal of Haematology, vol. 131, no. 2, pp. 172–179, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. D. Russo, G. Pricolo, M. Michieli et al., “Fludarabine, arabinosyl cytosine and idarubicin (FLAI) for remission induction in poor-risk acute myeloid leukemia,” Leukemia & Lymphoma, vol. 40, no. 3-4, pp. 335–343, 2001. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Rothenberg-Thurley, S. Amler, D. Goerlich et al., “Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia,” Leukemia, vol. 32, no. 7, pp. 1598–1608, 2018. View at Publisher · View at Google Scholar
  33. D. H. Spencer, D. A. Russler-Germain, S. Ketkar et al., “CpG island hypermethylation mediated by DNMT3A is a consequence of AML progression,” Cell, vol. 168, no. 5, pp. 801–816.e13, 2017. View at Publisher · View at Google Scholar · View at Scopus
  34. A. D. Kelly, J. Madzo, P. Madireddi et al., “Demethylator phenotypes in acute myeloid leukemia,” Leukemia, vol. 32, no. 10, pp. 2178–2188, 2018. View at Publisher · View at Google Scholar · View at Scopus
  35. Y. Qu, L. Siggens, L. Cordeddu et al., “Cancer-specific changes in DNA methylation reveal aberrant silencing and activation of enhancers in leukemia,” Blood, vol. 129, no. 7, pp. e13–e25, 2017. View at Publisher · View at Google Scholar · View at Scopus
  36. P. Hirsch, Y. Zhang, R. Tang et al., “Genetic hierarchy and temporal variegation in the clonal history of acute myeloid leukaemia,” Nature Communications, vol. 7, no. 1, 2016. View at Publisher · View at Google Scholar · View at Scopus
  37. C. C. Smith, A. Paguirigan, G. R. Jeschke et al., “Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis,” Blood, vol. 130, no. 1, pp. 48–58, 2017. View at Publisher · View at Google Scholar · View at Scopus
  38. N. Potter, F. Miraki-Moud, L. Ermini et al., “Single cell analysis of clonal architecture in acute myeloid leukaemia,” Leukemia, vol. 33, no. 5, pp. 1113–1123, 2019. View at Publisher · View at Google Scholar · View at Scopus
  39. C. M. McMahon, T. Ferng, J. Canaani et al., “Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia,” Cancer Discovery, vol. 9, no. 8, pp. 1050–1063, 2019. View at Publisher · View at Google Scholar